news
Keep up on Kalos news and follow developments about the innovative and promising treatments in our pipeline.
ValiRx PLC Agreement with Kalos Therapeutics:
(10 November 2020) ValiRx (AIM: VAL) a clinical stage drug development company, announces today that it has entered into an agreement with Kalos Therapeutics (Kalos), a US-based private biotechnology company, to evaluate its peptide KTH222 as a drug candidate for treating patients with ovarian cancer.
Kalos Therapeutics Announces Early Positive Data Against SARS-CoV-2 For COVID-19 Program:
(August 21, 2020) Kalos Therapeutics today announced positive preclinical efficacy results from a series of Kalos peptides for the treatment of COVID-19.
Kalos therapeutics announces important progress in therapeutic peptide for cancer program:
(May 30, 2020 ) Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer
(April 06, 2020) Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system.
© 2020 Kalos Therapeutics. All Rights Reserved.
This website makes use of cookies. Please see our privacy policy for details.
